Literature DB >> 29875141

Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

Mark R Schleiss1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29875141      PMCID： PMC6004476          DOI： 10.1073/pnas.1806420115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  30 in total

1.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

3.  Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.

Authors:  Adam C Finnefrock; Daniel C Freed; Aimin Tang; Fengsheng Li; Xi He; Chengwei Wu; Debbie Nahas; Dai Wang; Tong-Ming Fu
Journal:  Hum Vaccin Immunother       Date:  2016-03-17       Impact factor: 3.452

4.  Structure and composition of a family of human cytomegalovirus glycoprotein complexes designated gC-I (gB).

Authors:  B Kari; Y N Liu; R Goertz; N Lussenhop; M F Stinski; R Gehrz
Journal:  J Gen Virol       Date:  1990-11       Impact factor: 3.891

Review 5.  Strain Variation and Disease Severity in Congenital Cytomegalovirus Infection: In Search of a Viral Marker.

Authors:  Ravit Arav-Boger
Journal:  Infect Dis Clin North Am       Date:  2015-07-04       Impact factor: 5.982

6.  Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

Authors:  David I Bernstein; Flor M Munoz; S Todd Callahan; Richard Rupp; Susan H Wootton; Kathryn M Edwards; Christine B Turley; Lawrence R Stanberry; Shital M Patel; Monica M Mcneal; Sylvie Pichon; Cyrille Amegashie; Abbie R Bellamy
Journal:  Vaccine       Date:  2015-12-02       Impact factor: 3.641

Review 7.  Class III viral membrane fusion proteins.

Authors:  Marija Backovic; Theodore S Jardetzky
Journal:  Curr Opin Struct Biol       Date:  2009-04-06       Impact factor: 6.809

Review 8.  Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.

Authors:  Meghan S Vermillion; Sabra L Klein
Journal:  NPJ Vaccines       Date:  2018-02-01       Impact factor: 7.344

9.  Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Authors:  Ilona Baraniak; Barbara Kropff; Gary R McLean; Sylvie Pichon; Fabienne Piras-Douce; Richard S B Milne; Colette Smith; Michael Mach; Paul D Griffiths; Matthew B Reeves
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

10.  Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.

Authors:  Fengsheng Li; Daniel C Freed; Aimin Tang; Richard R Rustandi; Matthew C Troutman; Amy S Espeseth; Ningyan Zhang; Zhiqiang An; Michael McVoy; Hua Zhu; Sha Ha; Dai Wang; Stuart P Adler; Tong-Ming Fu
Journal:  NPJ Vaccines       Date:  2017-12-14       Impact factor: 7.344
View more
  8 in total

1.  Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.

Authors:  Cody S Nelson; Jennifer A Jenks; Norbert Pardi; Matthew Goodwin; Hunter Roark; Whitney Edwards; Jason S McLellan; Justin Pollara; Drew Weissman; Sallie R Permar
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 2.  Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.

Authors:  Yan Man; Zhixiang Lu; Xiangmei Yao; Yuemin Gong; Tonghua Yang; Yajie Wang
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

Review 3.  Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.

Authors:  Giuseppe Gerna; Daniele Lilleri
Journal:  Vaccines (Basel)       Date:  2020-04-23

Review 4.  The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.

Authors:  Ariane C Gomes; Paul D Griffiths; Matthew B Reeves
Journal:  Vaccines (Basel)       Date:  2019-07-17

5.  Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.

Authors:  Jennifer A Jenks; Cody S Nelson; Hunter K Roark; Matthew L Goodwin; Robert F Pass; David I Bernstein; Emmanuel B Walter; Kathryn M Edwards; Dai Wang; Tong-Ming Fu; Zhiqiang An; Cliburn Chan; Sallie R Permar
Journal:  Sci Transl Med       Date:  2020-11-04       Impact factor: 19.319

Review 6.  Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.

Authors:  Michela Perotti; Laurent Perez
Journal:  Viruses       Date:  2019-12-28       Impact factor: 5.048

7.  Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection.

Authors:  Mark R Schleiss; Don J Diamond
Journal:  Vaccines (Basel)       Date:  2020-09-14

Review 8.  Insight for Immunotherapy of HCMV Infection.

Authors:  Xinmiao Long; Yi Qiu; Zuping Zhang; Minghua Wu
Journal:  Int J Biol Sci       Date:  2021-07-13       Impact factor: 6.580
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.